Summit Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC was accepted by the FDA, despite the primary analysis not achieving statistically significant overall survival.
NASDAQ
Summit Therapeutics Inc. files its 10-K report, detailing financial results for 2024 and outlining progress in the clinical development of its lead candidate, ivonescimab.
NASDAQ
10-K: Summit Therapeutics Inc. Files 10-K Report, Outlines Financials and Strategic Focus on Oncology
Summit Therapeutics Inc.'s 10-K filing details its financial position, strategic shift to oncology, and ongoing development of ivonescimab.